The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday.

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could ...

Eli Lilly stated that results from a late-stage trial of its pill variant of GLP-1 drugs met the requirements for global ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Serena Williams has long been subjected to ill-tasted criticism over her weight. Her recent collaboration with a healthy ...

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

Are you a TRICARE beneficiary taking a drug for weight loss—such as a GLP-1 medication like Zepbound or Wegovy? Do you have ...

Tricare officials said the Defense Health Agency is eliminating coverage for its Tricare for Life beneficiaries and others to ...

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are also called GLP-1 medications, short for glucagon-like peptide-1 agonists, ...